News

The designation for pelareorep was supported by results from the phase 1/2 GOBLET study.

Phase 2 KEYPAD tests pembrolizumab plus denosumab after VEGFR TKI failure in ccRCC, showing 31% responses, 7.5-month PFS,

During a live event, Millie Das, MD, and participants discussed how long-term survival data are reshaping first-line treatment selection for patients with PD-L1–negative metastatic non–small cell lung cancer.

Phase 2 data show safusidenib drives deepening responses and durable control in IDH1‑mutant grade 2 glioma, prompting new trials for earlier and post‑vorasidenib use.

In an interview, Joseph Mikhael, MD, MEd, discussed the impact of the approval of subcutaneous isatuximab and its on-body delivery system in multiple myeloma.

TREASURE trial shows adding thoracic radiotherapy to atezolizumab maintenance in ES‑SCLC boosts fatal toxicity without survival gain.

Five-year WSG TP-II results suggest chemo-free endocrine therapy with dual HER2 blockade matches paclitaxel, with fewer severe side effects.

ENHANCE phase 3 results show that magrolimab added to azacitidine failed to boost remission or survival in higher-risk MDS and increased serious toxicity.

Long OMNIVORE follow-up shows select advanced RCC responders stop nivolumab and stay treatment-free for years; salvage ipilimumab adds little.

During a live event, Matthew Rettig, MD, examined treatment options for a patient who had received prior doublet therapy for metastatic castration-resistant prostate cancer.

Early trial shows off-the-shelf immunotherapy combo boosts responses in relapsed B-cell lymphoma with manageable CRS and safety.

The phase 2 OPTIMAL-e trial combines the PSMA-targeted radioligand therapy with standard ADT and ARPI in metastatic hormone-sensitive prostate cancer.

Adding investigational BPM31510 to standard chemoradiation may boost survival in newly diagnosed glioblastoma, especially MGMT-unmethylated tumors, with promising safety data.

The Himalayas-1 trial will investigate rinzimetostat in combination with darolutamide in patients who previously received abiraterone for metastatic castration-resistant prostate cancer.

INVINCIBLE-4 restarts testing intratumoral INT230-6 before neoadjuvant pembrolizumab chemotherapy in early TNBC, aiming to boost pCR while reducing severe side effects.

A phase 1 trial of the radiotherapeutic determined a recommended phase 2 dose after promising activity in heavily pretreated multiple myeloma.

A trend toward improvement in overall survival (OS) with pembrolizumab was observed; however, the OS data are not mature.

National BRFSS study reveals SOGI adults lag in cervical and breast cancer screening; gaps are linked to insurance, access, and stigma.

During an event, Julia Rotow, MD, and participants discussed how a real-world case of cascading anemia and thrombocytopenia shifted the group's thinking on multilineage prophylaxis for extensive-stage small cell lung cancer.

Real-world data link vitamin D supplements to longer watch-and-wait time before CLL treatment, prompting fresh debate on delaying progression.

Phase 3 data show TROP2 ADC sac-TMT plus pembrolizumab extends PFS in PD-L1–negative nonsquamous NSCLC, signaling a new first-line option.

Tucidinostat plus nivolumab extends progression-free survival in treatment-naive advanced melanoma, offering a promising oral, chemo-free boost to frontline immunotherapy.

Oncologists debate BTK inhibitor choices in relapsed CLL, exploring when MRD testing matters, toxicity management, and insurance hurdles.

Phase 3 VIKTORIA-1 results show that gedatolisib combinations extend progression-free survival in PIK3CA-mutated breast cancer, with strong response rates and manageable stomatitis.

FDA gives full approval to selpercatinib for RET fusion solid tumors, backed by 47% response rate and long-lasting benefit across cancers.

Analyses of the CASSIOPEIA trial showed that some patients' outcomes could be associated with disease features besides depth of response alone.

Phase 3 China trial shows B7-H3 ADC risvutatug rezetecan extends survival vs topotecan in relapsed SCLC, signaling a promising new option.

During a live event, Sapna Patel, MD, and participants discussed second-line treatment selection for a patient with mucosal melanoma and considered how the limited available data shape that choice.